FDA approves first ever treatment for neurofibromatosis

(Children's Tumor Foundation) The FDA has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1). The FDA's approval of AstraZeneca's and MSD (Merck)'s submission is a major milestone for patients living with neurofibromatosis (NF), a genetic disorder that causes tumors to grow on nerves throughout the body. Affecting 1 in 3,000 people of all populations equally, this announcement is the first ever approved treatment for NF.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news